TABLE 1.
Descriptive presentation of PIs performed with acceptance status entered.
| Pharmacist | |
| Postgraduate pharmacist | 1,426 (48.7%) |
| Pharmacy resident | 1,504 (51.3%) |
| Prescriber | |
| Postgraduate physician | 802 (27.4%) |
| Medical resident | 2,128 (72.6%) |
| Patient gender | |
| Male | 1,421 (48.5%) |
| Female | 1,509 (51.5%) |
| Patient age | |
| ≤59 | 773 (26.4%) |
| 60–69 | 595 (20.3%) |
| 70–79 | 569 (19.4%) |
| 80–89 | 682 (23.3%) |
| ≥90 years | 311 (10.6%) |
| Problem encountered | |
| Non-compliance with guidelines and contraindications | 687 (23.4%) |
| Untreated indication | 329 (11.2%) |
| Underdosing | 392 (13.4%) |
| Overdosing | 559 (19.1%) |
| Drug not indicated | 203 (6.9%) |
| Drug interaction | 135 (4.6%) |
| Adverse effect | 57 (1.9%) |
| Inappropriate route and/or administration | 267 (9.1%) |
| Treatment not received | 2 (0.1%) |
| Monitoring to be followed | 299 (10.2%) |
| Type of intervention | |
| Addition | 413 (14.1%) |
| Discontinuation | 497 (17%) |
| Substitution/Exchange | 358 (12.2%) |
| Choice of route of administration | 14 (0.5%) |
| Therapeutic follow-up | 385 (13.1%) |
| Optimization of administration modalities | 255 (8.7%) |
| Dosage adjustment | 1,008 (34.4%) |
| Method of contact | |
| Verbal | 1,623 (55.4%) |
| Phone call | 455 (15.5%) |
| Prescription assistance software | 846 (28.9%) |
| Paper | 6 (0.2%) |
| Clinical impact on patient health | |
| None | 41 (1.4%) |
| Minor | 570 (19.5%) |
| Moderate | 1,317 (44.9%) |
| Major | 976 (33.3%) |
| Vital | 26 (0.9%) |
| Organizational impact | |
| Unfavorable | 89 (3%) |
| Nil | 2,130 (72.7%) |
| Favorable | 711 (24.3%) |
| Economic impact | |
| Unfavorable | 788 (26.9%) |
| Nil | 1,172 (40%) |
| Favorable | 970 (33.1%) |
| ATC class | |
| A Digestive tract and metabolism | 409 (14%) |
| B Blood and blood-forming organs | 508 (17.3%) |
| C Cardiovascular system | 272 (9.3%) |
| D Dermatological drugs | 8 (0.3%) |
| G Genitourinary system and sex hormones | 33 (1.1%) |
| H Systemic hormones, excluding sex hormones | 74 (2.5%) |
| J General anti-infectives for systemic use | 887 (30.3%) |
| L Antineoplastics and immunomodulators | 68 (2.3%) |
| M Muscle and skeleton | 37 (1.3%) |
| N Nervous system | 547 (18.7%) |
| P Antiparasitic insecticides | 7 (0.2%) |
| R Respiratory system | 44 (1.5%) |
| S Sensory organs | 14 (0.5%) |
| V Miscellaneous | 19 (0.6%) |
| Z Drug with no code assigned | 3 (0.1%) |
| PI at reconciliation | |
| No | 2,586 (88.3%) |
| Yes | 344 (11.7%) |
| PI using Pharmaclass® | |
| No | 2,786 (95.1%) |
| Yes | 144 (4.9%) |
| Validation setting | |
| Within the pharmacy | 1,096 (37.4%) |
| Within the ward | 1,834 (62.6%) |
| Care unit | |
| Nursing home | 282 (9.6%) |
| Medicine-surgery-obstetrics departments, excluding resuscitation | 1,931 (65.9%) |
| Resuscitation | 717 (24.5%) |
| Number of drugs per PI | |
| 1 | 2,349 (80.2%) |
| 2 | 499 (17%) |
| 3 | 51 (1.7%) |
| 4 | 31 (1.1%) |